Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Behcet's disease-related uveitis
ChiCTR1900027147Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in Behçet's disease (BD) and uveitis, sponsored by Zhongshan Ophthalmic Center. Primary endpoints: Vision and Anterior uveitis activity. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
03
Conditions
Behçet's disease (BD)uveitis
Beyond the preview
Go deeper on ChiCTR1900027147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027147.